Literature DB >> 15386809

Lymphatic system changes in diabetes mellitus: role of insulin and hyperglycemia.

P Moriguchi1, P Sannomiya, P F Lara, R M Oliveira-Filho, K V Greco, L S Sudo-Hayashi.   

Abstract

BACKGROUND: Diabetic alterations of blood vessels have been well studied, but much less is known about the lymphatic system, which plays an important role in the transport of particles and defensive responses. Accordingly, we investigated lymphatic changes in diabetic rats.
METHODS: Ten, 30 or 60 days after alloxan-induced diabetes (40 mg/kg; i.v.), we studied thoracic duct lymph flow and lymphocyte output, thoracic duct lymph transport of radiotracer particles ((99m)Tc-dextran 500), lymph node uptake and scintigraphic visualization of subcutaneously injected radiotracer particles, as well as the effect of insulin administration and food deprivation.
RESULTS: Diabetes significantly increased thoracic duct lymph flow and the transport of dextran from the footpad subcutaneous tissue. Abnormal lymphocyte output from the thoracic duct occurred in the first 10 days. Uptake of dextran into regional lymph nodes was decreased in diabetes. Insulin per se, although not normalizing blood sugar levels, appeared to recover thoracic duct lymphocyte output and lymph node uptake of (99m)Tc-dextran 500 without affecting the thoracic duct lymph flow or the amount of radiotracer recovered therein. Normalization of glycemia (by food deprivation) restored the lymph flow to control levels without modifying the lymphocyte output. On the other hand, under insulin-restored normoglycemic conditions, both the thoracic duct lymph flow and the lymphocyte output were normalized.
CONCLUSIONS: These findings suggest that variables related to defensive mechanisms, such as lymphocyte recirculation and particles uptake into the lymph nodes can benefit from insulin treatment, whereas glycemic control can benefit transport mechanisms in the lymphatic system, such as lymph flow and lymphatic transport of particles. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15386809     DOI: 10.1002/dmrr.500

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  20 in total

Review 1.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

Review 2.  Preclinical lymphatic imaging.

Authors:  Fan Zhang; Gang Niu; Guangming Lu; Xiaoyuan Chen
Journal:  Mol Imaging Biol       Date:  2011-08       Impact factor: 3.488

3.  Insulin modulates inflammatory and repair responses to elastase-induced emphysema in diabetic rats.

Authors:  Antonio Di Petta; Karin V Greco; Eveline O Castro; Fernanda D T Q S Lopes; Milton A Martins; Vera L Capelozzi; Luiz F P Moreira; Paulina Sannomiya
Journal:  Int J Exp Pathol       Date:  2011-09-22       Impact factor: 1.925

Review 4.  Inflammation-associated lymphangiogenesis: a double-edged sword?

Authors:  Honsoul Kim; Raghu P Kataru; Gou Young Koh
Journal:  J Clin Invest       Date:  2014-03-03       Impact factor: 14.808

5.  Impact of diabetes against the future risk of developing gout.

Authors:  García Rodríguez; Lucia Cea Soriano; Hyon K Choi
Journal:  Ann Rheum Dis       Date:  2010-06-22       Impact factor: 19.103

Review 6.  Lymphatic lipid transport: sewer or subway?

Authors:  J Brandon Dixon
Journal:  Trends Endocrinol Metab       Date:  2010-06-11       Impact factor: 12.015

7.  Insulin modulates cytokine release and selectin expression in the early phase of allergic airway inflammation in diabetic rats.

Authors:  Joilson O Martins; Carlos A L Campos; José W M C Cruz; Simone Manzolli; Venâncio A F Alves; Elcio O Vianna; Sonia Jancar; Paulina Sannomiya
Journal:  BMC Pulm Med       Date:  2010-07-28       Impact factor: 3.317

8.  Population Pharmacokinetic Modeling of Tapentadol Extended Release (ER) in Healthy Subjects and Patients with Moderate or Severe Chronic Pain.

Authors:  Dymphy R Huntjens; Lia C Liefaard; Partha Nandy; Henk-Jan Drenth; An Vermeulen
Journal:  Clin Drug Investig       Date:  2016-03       Impact factor: 2.859

9.  Differences in limb volume trajectories after breast cancer treatment.

Authors:  Betty Smoot; Bruce A Cooper; Yvette Conley; Kord Kober; Jon D Levine; Judy Mastick; Kimberly Topp; Christine Miaskowski
Journal:  J Cancer Surviv       Date:  2015-12-18       Impact factor: 4.442

10.  Epsin deficiency promotes lymphangiogenesis through regulation of VEGFR3 degradation in diabetes.

Authors:  Hao Wu; H N Ashiqur Rahman; Yunzhou Dong; Xiaolei Liu; Yang Lee; Aiyun Wen; Kim Ht To; Li Xiao; Amy E Birsner; Lauren Bazinet; Scott Wong; Kai Song; Megan L Brophy; M Riaj Mahamud; Baojun Chang; Xiaofeng Cai; Satish Pasula; Sukyoung Kwak; Wenxia Yang; Joyce Bischoff; Jian Xu; Diane R Bielenberg; J Brandon Dixon; Robert J D'Amato; R Sathish Srinivasan; Hong Chen
Journal:  J Clin Invest       Date:  2018-08-13       Impact factor: 19.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.